{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:51:27Z","timestamp":1769601087592,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":284,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.semnephrol.2023.151427","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:30:18Z","timestamp":1697567418000},"page":"151427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Joshua J.","family":"Neumiller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radica Z.","family":"Alicic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2023.151427_bib0001","unstructured":"International Diabetes Federation. IDF diabetes atlas. Accessed June 1, 2023. https:\/\/diabetesatlas.org\/atlas\/tenth-edition"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0002","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc23-Sint","article-title":"Standards of care in diabetes \u20132023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0003","unstructured":"United States Renal Data System (USRDS). Epidemiology of kidney disease in the United States. 2021. Accessed June 1, 2023. https:\/\/usrds-adr.niddk.nih.gov\/2021"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0004","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0005","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0006","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0007","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12902-022-01026-2","article-title":"Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER","volume":"22","author":"Arnold","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0010","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0011","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0012","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0013","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0015","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0016","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"77","author":"Tuttle","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0018","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE Trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0019","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1007\/s00125-021-05524-1","article-title":"Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program","volume":"64","author":"Young","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0020","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0021","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2337\/dc21-1744","article-title":"Association of baseline HbA1c with cardiovascular and renal outcomes: analyses from DECLARE-TIMI 58","volume":"45","author":"Cahn","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0022","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0023","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0026","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0028","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0029","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0030","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0031","unstructured":"National Institutes of Health (NIH) US National Library of Medicine. Research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). Accessed May 31, 2023. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819153"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0032","unstructured":"National Institutes of Health (NIH) US National Library of Medicine. A research study to find out how semaglutide works in the kidneys compared to placebo, in people with type 2 diabetes and chronic kidney disease (REMODEL). 2021. Accessed May 31, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04865770"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0033","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0034","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0036","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0037","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0038","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0039","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in diabetes: an update of basic mechanisms and clinical disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41581-020-00391-2","article-title":"SGLT2 inhibitors may offer benefit beyond diabetes","volume":"17","author":"Kang","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0041","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0042","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0043","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0044","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0045","doi-asserted-by":"crossref","first-page":"F1209","DOI":"10.1152\/ajprenal.00710.2012","article-title":"Adenosine inhibits renin release from juxtaglomerular cells via an A1 receptor-TRPC-mediated pathway","volume":"305","author":"Ortiz-Capisano","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0046","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0047","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0048","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0049","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0050","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"Clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0052","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0053","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0054","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0055","unstructured":"Food and Drug Administration (FDA). Kerendia (finerenone) prescribing information. Updated September 2022. Accessed October 2023. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Kerendia_PI.pdf."},{"key":"10.1016\/j.semnephrol.2023.151427_bib0056","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0057","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0058","unstructured":"Centers for Disease Control (CDC) and Prevention. National Diabetes Statistics Report. 2022. Accessed May 31, 2023. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html"},{"key":"10.1016\/j.semnephrol.2023.151427_bib0059","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/dc20-0978","article-title":"Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT","volume":"44","author":"Abdul-Ghani","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:46:09Z","timestamp":1748357169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0270929523001377"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151427","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151427"}}